Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.39 |
| ▸ | LIMK1 | P53667 | 5/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 7/20 | 0.38 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.37 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2440919 | 0.86 | LIMK1 (0.48) | LIMK1ADORA2A | |
| SCHEMBL2444868 | 0.83 | CTSA (0.41) | LIMK1ADORA2A | |
| SCHEMBL21091358 | 0.78 | HPGD (0.43) | IDO1LIMK1 | |
| SCHEMBL2403892 | 0.75 | PIK3CD (0.37) | LIMK1ADORA2A | |
| SCHEMBL12947909 | 0.71 | ALDH1A1 (0.43) | IDO1LIMK1ADORA2A | |
| SCHEMBL5536337 | 0.71 | CASR (0.42) | IDO1 | |
| SCHEMBL21091598 | 0.71 | LIMK1 (0.37) | LIMK1ADORA2A | |
| SCHEMBL2405326 | 0.71 | AOC3 (0.44) | ADORA2ACNR1 | |
| SCHEMBL2435795 | 0.70 | PTPN11 (0.51) | P2RX7NOTUM | |
| SCHEMBL17194976 | 0.70 | PDE3B (0.33) | LIMK1ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | HCRTR2, HCRTR1, HRH3 | IDO1 993/4885P2RX7 216/4885LIMK1 4439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.